Drugs / JT-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05331222 | Sep 2022 → Mar 2023 | chronic rhinitis, chronic rhinosinusitis | Jantar GmbH | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JT-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05331222 ↗ |
| Known as | Jantar-1 | “Jantar-1 (JT-1), 7% (w/w) aqueous solution” NCT05331222 ↗ |
| Route | Intranasal | “Proof-of-Concept Interventional Study With a Nasal Spray of JT-1 in Patients With Chronic Rhinitis or Chronic Sinusitis” NCT05331222 ↗ |